ARTICLE | Clinical News
SBC-103 regulatory update
July 29, 2013 7:00 AM UTC
The European Commission granted Orphan Drug designation for Synageva's SBC-103 to treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B syndrome). Next half, Synageva plans to start clinical testi...